Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02933944
Recruitment Status : Terminated (Changing priorities)
First Posted : October 14, 2016
Last Update Posted : June 14, 2019
Sponsor:
Information provided by (Responsible Party):
Targovax ASA

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : February 2019
Study Completion Date : No date given
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 September 16, 2021